Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico Ii, Naples, Italy.
Dermatology Department, Universidad Autónoma de Nuevo León, University Hospital ¨Dr. José Eleuterio González¨, Monterrey, Mexico.
Expert Opin Drug Saf. 2022 Jan;21(1):21-29. doi: 10.1080/14740338.2022.1993819. Epub 2021 Nov 1.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent malignant skin cancer, with an increasing worldwide incidence. Cemiplimab is a human monoclonal antibody directed against programmed cell death-1 receptor that acts by blocking T-cell inactivation. It is the first drug approved for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
The aim of this review is to analyze the mechanism of action, including pharmacokinetic and pharmacodynamic properties, clinical efficacy, safety, and tolerability of cemiplimab for squamous cell carcinoma.
The introduction of immune checkpoint inhibitors has revolutionized the therapeutic scenario of advanced skin cancers. Many challenges regarding the use of cemiplimab for locally advanced and metastatic CSCC still exist. The use of combination treatments, including the association of different immune checkpoint inhibitors, could be a strategy to increase treatment response, reducing the possibility of therapeutic failure. Also, different schemes of treatment or dose adjustments should be considered in order to reduce toxicity, avoiding treatment discontinuation and increasing patient´s quality of life.
皮肤鳞状细胞癌（CSCC）是第二常见的恶性皮肤癌，其全球发病率呈上升趋势。西米普利单抗是一种针对程序性死亡受体 1 的人源化单克隆抗体，通过阻断 T 细胞失活起作用。它是第一种被批准用于治疗不适合治愈性手术或治愈性放疗的转移性或局部晚期皮肤鳞状细胞癌成年患者的药物。
本综述旨在分析西米普利单抗治疗鳞状细胞癌的作用机制，包括药代动力学和药效学特性、临床疗效、安全性和耐受性。
免疫检查点抑制剂的引入彻底改变了晚期皮肤癌的治疗格局。关于西米普利单抗在局部晚期和转移性 CSCC 中的应用仍存在许多挑战。联合治疗的使用，包括不同免疫检查点抑制剂的联合，可能是提高治疗反应、降低治疗失败可能性的一种策略。此外，为了降低毒性，避免治疗中断和提高患者生活质量，应考虑不同的治疗方案或剂量调整。
